Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Defining Retroviruses
-
1. An introduction to retroviruses: replication strategy and genetics
- Dr. Jonathan Stoye
-
2. Bovine leukemia virus
- Prof. Arsene Burny
- Dr. Lucas Willems
- The First Human Retroviruses
-
3. The discovery of human retroviruses and how they cause disease
- Prof. Robert Gallo
- HIV - Peculiarities of its Genome
-
4. HIV: peculiarities of its genome
- Dr. George Pavlakis
- HIV Transmission, Epidemiology and Public Health/Prevention Issues
-
5. HIV/AIDS epidemiology, transmission, and risk factors
- Prof. William Blattner
-
6. HIV prevention and public health issues: a global perspective
- Prof. Sten H. Vermund
- How HIV causes AIDS
-
7. How HIV causes disease 1: identification and characterization of HIV
- Prof. Bruce Walker
-
8. How HIV causes disease 2: immune responses to HIV infection
- Prof. Bruce Walker
- HIV Therapy - Now and the Future
-
9. HIV therapy: taking advantage of progress
- Prof. Paul Volberding
-
10. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Archived Lectures *These may not cover the latest advances in the field
-
11. The first human retroviruses: the human T lymphotropic viruses (HTLVs)
- Prof. William Hall
-
12. HIV preventive vaccines
- Prof. Andrew McMichael
-
13. HIV/AIDS in the developing world: what can we do?
- Dr. Joseph O'Neill
-
15. Antiretroviral therapy 2007, new concepts and lessons learned
- Prof. Robert Redfield
-
16. What to do in therapy in the face of HIV drug resistance?
- Prof. Mark Wainberg
-
17. Viral reservoirs, latency and mechanisms of HIV persistence
- Prof. Robert Siliciano
-
18. HIV preintegration complexes
- Prof. Lee Ratner
-
19. The discovery of ATL field expansion in 40 yrs
- Prof. Junji Yodoi
Printable Handouts
Navigable Slide Index
- Introduction
- HIV - the greatest pandemic
- Adults and children living with HIV: 2016
- Global distribution of subtypes
- Adults and children living with HIV: 1990–2016
- Children (<15 years) living with HIV: 2016
- Estimated adult and child deaths from AIDS: 2016
- Magnitude of HIV deaths: 2016
- Adult & child deaths due to AIDS: 1990–2016
- Declining mortality due to HIV: 2000-2015
- High mortality in low income countries: 2015
- Estimated deaths in children (<15 years): 2016
- Adults & children newly infected with HIV: 2016
- Adults & children newly infected with: 1990-2016
- HIV infections averted through condom use
- Number of children newly infected with HIV: 2016
- 5,000 new Infections a day: 2016
- Emerging patterns of HIV infection (1)
- Emerging patterns of HIV infection (2)
- Emerging patterns of HIV infection (3)
- HIV infections by population, globally, 2014
- Subnational HIV incidence among young women
- Key population concentrated epidemic: Nigeria
- Modeling of attributable fraction of transmission
- Varied patterns of HIV transmission
- HIV infection
- Routes of transmission of HIV
- Risk factors for injection drug users
- Viral factors in transmission
- HIV viral load and transmission
- Implications of viral subtype
- Host factors in transmission
- Non circumcision and transmission
- “Ecologic” factors in transmission
- STD heightens local genital viral load
- Intrauterine and peri-partum transmission
- Breast feeding transmission
- HIV-1 RNA levels at delivery and antiretroviral use
- HPTN 052 study design
- HPTN 052: HIV-1 transmission (1)
- HPTN 052: HIV-1 transmission (2)
- Viral load – Temprano-ANRS 12126
- Last sexual partnership at M12V: Temprano-ANRS
- Estimated HIV transmission: Temprano-ANRS
- Ending the HIV/AIDS epidemic by 2030
- Number of people receiving treatment
- Number of people newly infected with HIV
- Number of people dying from HIV
- HIV testing and treatment cascade improvement
- Summary (1)
- Summary (2)
- Thank you
Topics Covered
- Introduction to scope and impact of the HIV/AIDS global epidemic
- Emerging trends in HIV infection reflecting underlying population characteristics
- Mechanisms and risk factors for HIV infection
- Viral and host factors that impact HIV spread
- Emerging insights about treatment as prevention
- Framework for ending the HIV epidemic through the 90 90 90 framework
- Current challenges to meeting 90 90 90 framework goals
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Blattner, W. (2018, November 29). HIV/AIDS epidemiology, transmission, and risk factors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/HUKJ1908.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. William Blattner has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
HIV/AIDS epidemiology, transmission, and risk factors
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
In this lecture, I will be presenting the epidemiology of HIV and AIDS,
its transmission and risk factors,
and provide a current update of recent trends that point to
the potential of achieving the goal of containment of this epidemic in the coming years.
But first, let me introduce myself.
I'm William A. Blattner.
I'm a medical physician.
I've been involved in the HIV epidemic since before 1981,
as my group was involved in the detection of one of
the first cases of kaposi sarcoma before
the June 1981 CDC publication that identified the first cases of pneumocystis.
Since then I've been a member of the team the co-discover the HIV virus.
Subsequently, I went on to co-found
the Institute of Human Virology at the University of Maryland, School of Medicine.
I recently transitioned from my academic posts as a full professor
to now being involved as a consultant through Saltrun Global Health and Research.
1:10
Since 1981, over 60 million persons worldwide have become
infected and are living with or have died from HIV infections.
Shown in this slide is an electron micrograph and a schematic of the HIV virus.
It's a lenti retrovirus.
It has an RNA genome that uses an enzyme of the virus to make a DNA copy,
and thus is able to become part of the genetic material of the host target cell.
Thus, HIV in essence,
becomes a new gene within the body,
which explains why it's been so difficult to totally
eliminate the virus from persons who are infected,
and thus the challenge that is facing medical science in achieving a cure.
But that having been said,
as I'll detail later,
treatments have become very effective and have created
a circumstance where people can live a full life on antiretroviral therapy.
In the meantime, the virus because of its great ability to change,
which is hundreds or thousands or millions of times more diverse than even the flu virus,
for example, have hampered the ability to develop a preventative vaccine.